Last edition
News about "Ruud Dobber"
EU Approves Trixeo for Asthma Maintenance Treatment
Trixeo is approved in the EU for asthma maintenance treatment, becoming the first and only triple-combination therapy for patients aged 12 years and older.
Ruud Dobber | 24/09/2026 | By News Bureau
CHMP Recommends AstraZeneca's Trixeo for EU Approval in Asthma
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended EU approval of AstraZeneca's Trixeo for asthma maintenance, backed by positive phase 3 KALOS and LOGOS trial results.
Ruud Dobber | 25/07/2026 | By News Bureau | 220
AstraZeneca Wins US Approval for Baxfendy, First Aldosterone Synthase Inhibitor for Hypertension
AstraZeneca receives US approval for Baxfendy, the first Aldosterone Synthase Inhibitor (ASI) for adults with hypertension, supported by phase 3 BaxHTN trial results showing significant reductions in systolic blood pressure.
Ruud Dobber | 20/05/2026 | By News Bureau | 139
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy